John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announces that the United States Patent and Trademark Office awarded a patent on its lead compound, LB-100, as well as a number of structurally related compounds, which has shown promising anti-cancer activity. Patent applications on these compounds are pending world wide. Lixte is presently completing pre-clinical studies of LB-100 in preparation for submitting an application to the Food and Drug Administration to conduct Phase I trials.
John Kovach, MD, founder and president of Lixte said, "We are extremely pleased that that LB-100 and several structurally related compounds have been recognized as novel potential anti-cancer compounds. LB-100 is an anti-cancer compound, which appears to prevent cancer cells from defending themselves against standard types of cancer treatments. In pre-clinical animal model systems, LB-100 enhances the killing of cancer cells by several widely used anti-cancer drugs as well as radiation treatments. If the improved anti-cancer activity of LB-100 combined with conventional anti-cancer treatments seen in animals is borne out against human cancers without undue toxicity, we hope that LB-100 may be associated with meaningful benefit to patients with several types of cancer."
Triple-negative breast cancer patients with high immune cell levels have lower relapse risk after surgery